Egen Jackson G, Kuhns Michael S, Allison James P
Howard Hughes Medical Institute, Department of Molecular and Cell Biology, Cancer Research Laboratory, University of California at Berkeley, Berkeley, CA 94720, USA.
Nat Immunol. 2002 Jul;3(7):611-8. doi: 10.1038/ni0702-611.
The discovery of multiple costimulatory cell surface molecules that influence the course of T cell activation has increased our appreciation of the complexity of the T cell response. It remains clear, however, that CD28 and cytotoxic T lymphocyte antigen 4 (CTLA-4) are the critical costimulatory receptors that determine the early outcome of stimulation through the T cell antigen receptor (TCR). Details of how the T cell integrates TCR stimulation with the costimulatory signals of CD28 and the inhibitory signals of CTLA-4 remain to be established, but unique features of the cell biology of CTLA-4 provide important insights into its function. We summarize here recent findings that suggest a previously unrecognized role for CTLA-4 in the regulation of T cell responses. We also describe preclinical and clinical results that indicate manipulation of CTLA-4 has considerable promise as a strategy for the immunotherapy of cancer.
多种影响T细胞激活过程的共刺激细胞表面分子的发现,让我们更加认识到T细胞反应的复杂性。然而,很明显,CD28和细胞毒性T淋巴细胞抗原4(CTLA-4)是决定通过T细胞抗原受体(TCR)刺激的早期结果的关键共刺激受体。T细胞如何将TCR刺激与CD28的共刺激信号和CTLA-4的抑制信号整合起来的细节仍有待确定,但CTLA-4细胞生物学的独特特征为其功能提供了重要见解。我们在此总结了最近的研究发现,这些发现提示CTLA-4在调节T细胞反应中具有此前未被认识到的作用。我们还描述了临床前和临床结果,这些结果表明,操纵CTLA-4作为一种癌症免疫治疗策略具有很大的前景。